Skip to content

Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults: a preliminary study.

Christine A Rabinak, Ashley Blanchette, Nicole L Zabik, Craig A Peters, Hilary A Marusak, Allesandra Iadipaolo, Farrah Elrahal

Psychopharmacology June 2020 DOI: 10.1007/s00213-020-05499-8 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized, double-blind, placebo-controlled, between-subjects experimental study Peer reviewed
Sample size 71
Population Adults in three groups: non-trauma-exposed healthy controls (n=25), trauma-exposed adults without PTSD (n=27), and trauma-exposed adults with PTSD (n=19)
Intervention THC
Dose low dose
Topics PTSD
Keywords Amygdala Cannabinoid Prefrontal cortex Threat processing
Key findings In adults with PTSD, an acute low dose of THC lowered threat-related amygdala reactivity, increased medial prefrontal cortex activation during threat, and increased mPFC-amygdala functional coupling. The authors present these as preliminary data suggesting THC modulates threat-related processing in trauma-exposed individuals with PTSD and may be advantageous as a pharmacological approach to treating stress- and trauma-related psychopathology.

Abstract

Excessive fear and anxiety, coupled with corticolimbic dysfunction, are core features of stress- and trauma-related psychopathology, such as posttraumatic stress disorder (PTSD). Interestingly, low doses of ∆9-tetrahydrocannabinol (THC) can produce anxiolytic effects, reduce threat-related amygdala activation, and enhance functional coupling between the amygdala and medial prefrontal cortex and adjacent rostral cingulate cortex (mPFC/rACC) during threat processing in healthy adults. Together, these findings suggest the cannabinoid system as a potential pharmacological target in the treatment of excess fear and anxiety. However, the effects of THC on corticolimbic functioning in response to threat have not be investigated in adults with trauma-related psychopathology. To address this gap, the present study tests the effects of an acute low dose of THC on corticolimbic responses to threat in three groups of adults: (1) non-trauma-exposed healthy controls (HC; n = 25), (2) trauma-exposed adults without PTSD (TEC; n = 27), and (3) trauma-exposed adults with PTSD (n = 19). Using a randomized, double-blind, placebo-controlled, between-subjects design, 71 participants were randomly assigned to receive either THC or placebo (PBO) and subsequently completed a well-established threat processing paradigm during functional magnetic resonance imaging. In adults with PTSD, THC lowered threat-related amygdala reactivity, increased mPFC activation during threat, and increased mPFC-amygdala functional coupling. These preliminary data suggest that THC modulates threat-related processing in trauma-exposed individuals with PTSD, which may prove advantageous as a pharmacological approach to treating stress- and trauma-related psychopathology.

Comparable studies

Other randomized controlled trials on PTSD, most cited first.

Study Year Design Participants
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Patients with severe PTSD, including those with comorbidities such as dissociation,... 2021 Randomized controlled trial n = 90
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Patients with chronic post-traumatic stress disorder refractory to both psychotherapy... 2010 Randomized controlled trial n = 20
Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder Patients with chronic PTSD related to a range of trauma exposures 2014 Randomized controlled trial n = 41
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Military veterans and first responders aged 18 or older with chronic PTSD lasting 6... 2018 Randomized, double-blind, dose-response, phase 2 clinical trial n = 26
A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD) Patients with treatment-resistant PTSD 2012 Randomized controlled trial n = 12

Citations in the library

Cited by 7

and 2 more in the library

Cites 12

and 7 more in the library

Explore topics